Shares of Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX – Get Free Report) dropped 7.5% during trading on Monday. The stock traded as low as $28.60 and last traded at $29.0160. 18,215 shares were traded during mid-day trading, a decline of 81% from the average session volume of 95,396 shares. The stock had previously closed at $31.37.
Analyst Upgrades and Downgrades
NBTX has been the subject of a number of research analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nanobiotix in a research report on Thursday, October 15th. Guggenheim started coverage on Nanobiotix in a research report on Tuesday, September 15th. They issued a “buy” rating and a $64.00 target price on the stock. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $46.67.
View Our Latest Analysis on Nanobiotix
Nanobiotix Trading Up 1.6%
The company has a fifty day simple moving average of $32.00 and a two-hundred day simple moving average of $33.79.
Nanobiotix Company Profile
Nanobiotix is a biotechnology company developing nanoparticle-based therapies designed to improve the effectiveness of radiotherapy in cancer treatment. The company’s technology uses hafnium oxide nanoparticles that are injected directly into a tumor and activated by ionizing radiation, with the goal of increasing energy deposition within cancer cells while limiting exposure to surrounding tissue.
Nanobiotix’s lead product candidate, NBTXR3, is being evaluated in clinical studies across several cancer types, including locally advanced head and neck cancer and other solid tumors.
See Also
- Five stocks we like better than Nanobiotix
- Tower Semiconductor’s Earnings Are Soaring—So Why Is Its Stock Down More Than 50%?
- Shopify’s Small Q3 Miss Triggered a Big Sell-Off: What’s Next?
- Can Oil’s Big Rally Deliver Reliable Income? 3 Energy Plays to Watch
- Marriott’s Earnings Beat Shows Why It’s More Than a Bet on Travel Demand
Receive News & Ratings for Nanobiotix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nanobiotix and related companies with MarketBeat.com's FREE daily email newsletter.
